NCT06422520
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06422520
Title A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors BeiGene
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | AUS

Facility Status City State Zip Country Details
Florida Cancer Specialist Research Institute Lake Nona RECRUITING Orlando Florida 32827-7400 United States Details
Dana Farber Cancer Institute RECRUITING Boston Massachusetts 02215-5418 United States Details
Washington University School of Medicine RECRUITING St Louis Missouri 63110-1010 United States Details
Next Oncology RECRUITING Austin Texas 78758 United States Details
The University of Texas Md Anderson Cancer Center RECRUITING Houston Texas 77030-4009 United States Details
Westmead Hospital RECRUITING Westmead New South Wales NSW 2145 Australia Details
St Vincents Hospital Melbourne RECRUITING Fitzroy Victoria VIC 3065 Australia Details
The Alfred Hospital RECRUITING Melbourne Victoria VIC 3004 Australia Details
One Clinical Research RECRUITING Nedlands Western Australia WA 6009 Australia Details
Beijing Cancer Hospital RECRUITING Beijing Beijing Municipality 100142 China Details
Guangxi Medical University Cancer Hospital COMPLETED Nanning Guangxi 530021 China Details
Hubei Cancer Hospital RECRUITING Wuhan Hubei 430079 China Details
Jilin Cancer Hospital RECRUITING Changchun Jilin 130021 China Details
Liaoning Cancer Hospital and Institute RECRUITING Shenyang Liaoning 110042 China Details
West China Hospital, Sichuan University RECRUITING Chengdu Sichuan 610041 China Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field